HCA Healthcare Reports Third Quarter 2026 Results
HCA Healthcare reported Q3 2026 revenue of $19.849 billion, up 3.6% year-over-year, with diluted EPS of $7.27 (+4.5%) and adjusted EPS of $7.22 (+3.7%). Net income declined 3.9% to $1.579 billion as the company absorbed an estimated $400 million pre-tax hit from a payer mix shift driven by patients losing exchange-based insurance coverage; same facility admissions rose 2.7% and ER visits climbed 5.1%.
Key figures
- Eps
- 7.27
- Revenue
- 19849000000
- Guidance
- Full year 2026 results now expected in the upper half of previously issued guidance ranges (FY26 revenue $77.0B-$79.5B, Adjusted EBITDA $15.4B-$16.1B, diluted EPS $28.70-$30.50)
- Revenue Yoy
- 3.6%
- Net income
- 1579000000
- Total debt
- 50493000000
- Adjusted eps
- 7.22
- Buyback cost
- 2970000000
- Buyback shares
- 7230000
- Net income yoy
- -3.9%
- Adjusted ebitda
- 3918000000
- Nine month revenue
- 59188000000
- Adjusted ebitda yoy
- 1.2%
- Operating cash flow
- 4461000000
- Payer mix headwind pretax
- 400000000
- Quarterly dividend per share
- 0.78
- Same facility admissions yoy
- 2.7%
- Buyback authorization remaining
- 4240000000
- Same facility equivalent admissions yoy
- 3.0%
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.